HepQuant Paticipates in Media Pitch Day
Fitzsimmons Innovation Community hosted its first Media Pitch Day. Check out the summary:HepQuant Announces Additions to the Executive Leadership Team to Drive Commercialization
Kelly R. Pitts, PhD, Chief Operating Officer; Carrie Mulherin, MBA, Chief Commercial Officer; Shailesh Chavan, MD, Chief Medical Officer; Paige Nardi, MBA VP Market Access Denver, CO – June 13, 2023 – HepQuant, LLC, a leader transforming the management of liver diseases, announces key additions to its executive leadership team….
Kelly R. Pitts, Ph.D., Appointed Chief Operating Officer
Medical Diagnostics Industry Veteran with Biotech and Biopharma Experience Will Guide Operations DENVER (Apr. 14, 2023) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced its has chosen Kelly R. Pitts, Ph.D., as its new Chief…
HepQuant Lab Moves to New Location Within Fitzsimons Innovation Community Campus
The HepQuant Lab has moved a short distance within the Fitzsimons Innovation Community Campus to Bioscience 1, located at 12635 E. Montview Blvd., Suite 175, Aurora, CO 80045. The new lab space is adjacent to our previous location where we’ve been for the past five years, according to HepQuant Chief…
Hepion Pharmaceuticals Announces Early Completion of Enrollment in Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial
Hepion Pharma Announces First Dosing in Phase 2b Clinical Trial with HepQuant Endpoints
HepQuant Lab Meets COLA – CLIA Quality Standards
DENVER (Aug. 24, 2022) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced that the HepQuant laboratory has achieved COLA accreditation for laboratory quality assurance. COLA is a third-party accreditation organization that ensures labs comply with federal…
Preliminary data from the HepQuant SHUNT-V Pivotal study presented at DDW® 2022
SAN DIEGO (May 24, 2022) — HepQuant, LLC, a Denver, Colorado-based company with a unique, patented and patent-pending technology for evaluating the liver in patients with chronic liver disease, today announced preliminary data from the SHUNT-V Pivotal study in oral and poster presentations at Digestive Disease Week® (DDW) 2022 in San Diego….